(Q38377264)

2 September 2017

1 reference

title

Drug Interactions With Direct-Acting Antivirals for Hepatitis C: Implications for HIV and Transplant Patients (English)

1 reference

2 September 2017

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25770114%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

author name string

Sarah Burgess

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25770114%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Nilufar Partovi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25770114%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Eric M Yoshida

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25770114%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Siegfried R Erb

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25770114%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Vladimir Marquez Azalgara

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25770114%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

language of work or name

English

0 references

publication date

13 March 2015

1 reference

Annals of Pharmacotherapy

2 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25770114%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

volume

49

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25770114%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25770114%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

page(s)

674-687

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25770114%20AND%20SRC:MED&resulttype=core&format=json

The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.

6 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1060028015576180

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015576180

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015576180

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015576180

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015576180

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015576180

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015576180

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015576180

Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015576180

Sofosbuvir: A Nucleotide NS5B Inhibitor for the Treatment of Chronic Hepatitis C Infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015576180

Induction effects of ritonavir: implications for drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015576180

Management of hepatitis C-infected liver transplant recipients at large North American centres: changes in recent years

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015576180

Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015576180

Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015576180

Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015576180

An interferon-free antiviral regimen for HCV after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015576180

Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015576180

Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015576180

Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015576180

Epidemiology of viral hepatitis and HIV co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015576180

The challenge of hepatitis C in the HIV-infected person

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015576180

HIV and hepatitis C coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015576180

A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015576180

Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015576180

Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015576180

Quantitative testing of liver function in relation to fibrosis in patients with chronic hepatitis B and C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015576180

21 January 2018

Identifiers

DOI

10.1177/1060028015576180

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25770114%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

1 reference